Assay Development and High Throughput Screening (ADHTS) Core

Indiana University Indianapolis, Indianapolis IN

Investigators

Linked publications, trials & patents

Abstract

PROJECT SUMMARY/ABSTRACT Assay Development and High Throughput Screening Core (ADHTS) The goal of the Assay Development and High Throughput Screening (ADHTS) Core of the Indiana University School of Medicine Purdue University TaRget Enablement to Accelerate Therapy Development for Alzheimer's Disease (IUSM-Purdue TREAT-AD) Center is to integrate sophisticated disease biology and drug discovery capabilities and create Target Enabling Packages for the study of emerging Alzheimer's disease (AD) hypotheses (beyond amyloid beta). Accomplishing this goal will create the foundation for new classes of therapeutics to treat Alzheimer's disease. The supportive mission of the ADHTS Core is to advance target validation and enable novel drug discovery opportunities for IUSM-Purdue TREAT-AD Center targets. In collaboration with the other technical cores, we will use an integrated target assessment approach to improve target validation and facilitate the selection of targets for enablement. This work supports the design and development of individual assays and assembly into a connected set of in vitro and in vivo assays capable of providing reliable data to support novel drug discovery. In addition, the ADHTS core will develop translational biomarker strategies that support dose setting in early clinical development, thereby decreasing drug discovery risk and providing a clear path to early clinical testing. Finally, the core will disseminate essential resources such as novel reagents, assay methodologies, and data. All resources will be made available to the Alzheimer's Disease research community through the Target Enabling Packages that are posted on the AD Knowledge Portal and through direct requests made to the Center for transfer of materials. The ADHTS core directly contributes to the success of the IUSM-Purdue TREAT-AD Center through delivery of target enablement packages for the next generation of biological targets. The connected scheme of biochemical, cellular, and in vivo assays will be capable of prosecuting robust Structure Activity Relationship studies with the intention of identifying clinical candidates coupled with enabling biomarker assays positioned for translation to early clinical testing.